Gobind Singh
Stock Analyst at HC Wainwright & Co.
(n/a)
# 3,300
Out of 4,479 analysts
14
Total ratings
5.88%
Success rate
-55.54%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPHM Reneo Pharmaceuticals | Reiterates: Buy | $30 | $1.51 | +1,886.75% | 3 | Sep 8, 2023 | |
| ANAB AnaptysBio | Assumes: Buy | $35 | $23.94 | +46.20% | 1 | Sep 19, 2022 | |
| ELEV Elevation Oncology | Assumes: Buy | $7.5 | $2.80 | +167.86% | 1 | Sep 19, 2022 | |
| IMUX Immunic | Assumes: Buy | $26 | $1.15 | +2,160.87% | 2 | Sep 19, 2022 | |
| PRTA Prothena Corporation | Initiates: Market Outperform | n/a | $20.39 | - | 1 | Nov 19, 2021 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | n/a | $34.59 | - | 4 | Nov 15, 2021 | |
| EVLO Evelo Biosciences | Maintains: Market Outperform | n/a | $0.04 | - | 2 | Nov 2, 2021 |
Reneo Pharmaceuticals
Sep 8, 2023
Reiterates: Buy
Price Target: $30
Current: $1.51
Upside: +1,886.75%
AnaptysBio
Sep 19, 2022
Assumes: Buy
Price Target: $35
Current: $23.94
Upside: +46.20%
Elevation Oncology
Sep 19, 2022
Assumes: Buy
Price Target: $7.5
Current: $2.80
Upside: +167.86%
Immunic
Sep 19, 2022
Assumes: Buy
Price Target: $26
Current: $1.15
Upside: +2,160.87%
Prothena Corporation
Nov 19, 2021
Initiates: Market Outperform
Price Target: n/a
Current: $20.39
Upside: -
Protagonist Therapeutics
Nov 15, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $34.59
Upside: -
Evelo Biosciences
Nov 2, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $0.04
Upside: -